UK’s ‘Pioneering’ Medicines Repurposing Program Delivers First License
Executive Summary
Now that the first license for a drug has been obtained in partnership with the program, work will begin to ensure other companies that make the product adopt the new licensed indication.
You may also be interested in...
European Opportunities Loom For Value Added Medicines
Upcoming opportunities facilitated by the EU’s pharma legislation review were highlighted at Medicines for Europe’s fifth annual value added medicines conference, held in Brussels this month. However, enthusiasm was tempered with acknowledgements that the European sector current lags behind the US and needs further reform to attract investment.
New Zealand Seeks Funding Applications For Rare Disorder Drugs
Applications from drug companies should also include a commercial proposal, says Pharmac.
England’s NICE Considers Challenges In Assessing Cost Effectiveness Of Alzheimer’s Drugs
Health technology assessment institute NICE is scheduled to appraise Eisai/Biogen’s lecanemab and Eli Lilly’s donanemab next year.